FAP-targeted radioligand therapy represents a novel therapeutic approach to targeting the CCA tumor microenvironment in FAP expressing CCA and may be useful in combination with other CCA molecular-targeted or immunotherapies. This evidence concerns the gene FAP and neoplasm.